Parexel International Corp. announced Monday the launch of a platform that is designed to simplify the clinical trial process for experimental drugs.
Headquartered in Waltham, Parexel provides services to pharmaceutical companies looking to develop and commercialize new drugs.
In a press release, Parexel said it is calling its new offering the Parexel MyTrials platform.
‘‘In recent years there has been an increase in the number of applications for managing the clinical trials process, but these independent systems are not necessarily compatible with each other, for example, forcing users to enter the same data multiple times in different applications,” Dr. Mark A. Goldberg, Parexel’s chief operating officer, said in a statement. “This disrupts optimal workflow and processes, resulting in an unintended loss of productivity. Sponsors and investigator site users are looking for a unified solution to plan, design, and conduct their clinical trial programs. With the availability of Parexel MyTrials, users will have a single place to access a comprehensive suite of applications, tools, metrics, and reports through full data integration and application convergence.”
Parexel made its announcement as many life sciences companies converge on Boston, which is playing host this week to an industry convention known as BIO.